VDDI Pharmaceuticals' business strategy is to in-license products at an early stage of development and carry out development of the products.

VDDI Pharmaceuticals has an active in-licensing program, specifically in the Infectious disease, oncology, and Cardiovascular fields. It is seeking novel molecules and technologies complementary to its existing programs.

The company out-licenses to corporate partners in a process consistent with current licensing practices between biotechnology companies and pharmaceutical marketing companies and will also participate in co-development programs. Licensees are expected, to the extent necessary, to participate in the remaining clinical development required to obtain final regulatory approval for the products licensed.
All of the products in the VDDI Pharmaceuticals portfolio are available for out-licensing and co-development proposals.

For licensing information contact Stephen Porter at